Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: Retrieving data. Wait a few seconds and try to cut or copy again.

[Prof Renato Lopes (Duke University Medical Center, US) talks about the data from the APOLLO trial (NCT04746339).

This randomized, double-blinded trial compared a DOAC, Apixaban 2.5 MG twice daily with placebo for 30 days. The trial assessed this intervention in outpatients with symptomatic SARS-CoV2 infection and risk factors for thrombosis. The primary outcome measure focused on number of days alive out of hospital or emergency department.

Questions:
-In 2020, you said that we "need less common sense" and more clinical trial evidence. After 2 years, where are we in relation to COVID-19?
-How does the Apollo trial compare to other trials looking at DOACS in patients with COVID-19?
-What is the data presented at ESC and how does it add to the existing evidence?
-What are the take-home messages and what is next?

Recorded on-site at ESC Congress 22, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ESC 2022: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID-19 | Prof Renato Lopes" передвинте ползунок вправо